Shares of MeiraGTx Holdings plc (NASDAQ:MGTX - Get Free Report) gapped up prior to trading on Friday . The stock had previously closed at $6.39, but opened at $6.60. MeiraGTx shares last traded at $6.55, with a volume of 7,006 shares traded.
Analyst Ratings Changes
MGTX has been the topic of several research analyst reports. Royal Bank of Canada boosted their price target on MeiraGTx from $9.00 to $11.00 and gave the company an "outperform" rating in a research note on Thursday, November 14th. Chardan Capital reaffirmed a "buy" rating and set a $36.00 target price on shares of MeiraGTx in a report on Monday, November 18th.
Get Our Latest Stock Report on MGTX
MeiraGTx Trading Up 3.4 %
The company has a debt-to-equity ratio of 0.86, a current ratio of 2.34 and a quick ratio of 2.34. The company's fifty day moving average is $5.54 and its 200-day moving average is $4.88. The stock has a market cap of $529.08 million, a PE ratio of -5.60 and a beta of 1.24.
Hedge Funds Weigh In On MeiraGTx
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Knoll Capital Management LLC purchased a new position in MeiraGTx in the 3rd quarter valued at approximately $5,212,000. Royce & Associates LP raised its stake in shares of MeiraGTx by 5.3% in the third quarter. Royce & Associates LP now owns 795,392 shares of the company's stock valued at $3,317,000 after acquiring an additional 40,000 shares in the last quarter. Erste Asset Management GmbH purchased a new position in MeiraGTx in the third quarter valued at $2,795,000. State Street Corp grew its stake in MeiraGTx by 0.9% during the 3rd quarter. State Street Corp now owns 574,727 shares of the company's stock worth $2,397,000 after purchasing an additional 5,251 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in MeiraGTx by 14.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 462,950 shares of the company's stock worth $1,949,000 after purchasing an additional 58,854 shares during the period. 67.48% of the stock is currently owned by hedge funds and other institutional investors.
About MeiraGTx
(
Get Free Report)
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.
Further Reading
Before you consider MeiraGTx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MeiraGTx wasn't on the list.
While MeiraGTx currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
